HIV-1 resistance mutations and plasma RNA during zidovudine plus zalcitabine combination therapy

被引：0
|
作者：
Sylvester, A
Caliendo, A
An, D
Savara, A
Byington, R
Strick, D
Lillaney, R
Sutton, L
Sepkowitz, K
Fischl, M
Simon, G
Lalezari, J
Mitsuyasu, R
DAquila, R
机构：
[1] NEW YORK HOSP,NEW YORK,NY 10021
[2] UNIV MIAMI,MIAMI,FL 33152
[3] WASHINGTON UNIV,ST LOUIS,MO
[4] UNIV CALIF SAN FRANCISCO,SAN FRANCISCO,CA 94143
[5] UNIV CALIF LOS ANGELES,LOS ANGELES,CA
[6] MASSACHUSETTS GEN HOSP,BOSTON,MA 02114
[7] HARVARD UNIV,SCH MED,BOSTON,MA
来源：
JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES AND HUMAN RETROVIROLOGY | 1995年 / 10卷
关键词：
D O I：
暂无
中图分类号：
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号：
100102 ;
摘要：
引用
收藏
页码：47 / 47
页数：1
相关论文
共 50 条
  • [41] Plasma HIV-1 RNA Levels During Antiretroviral Therapy: How Low Is Low Enough?
    Gandhi, Rajesh T.
    Deeks, Steven G.
    CLINICAL INFECTIOUS DISEASES, 2012, 54 (05) : 733 - 735
  • [42] QUANTIFICATION OF HIV-1 RNA IN PLASMA USING NASBA (TM) DURING HIV-1 PRIMARY INFECTION
    VANGEMEN, B
    KIEVITS, T
    SCHUKKINK, R
    VANSTRIJP, D
    MALEK, LT
    SOOKNANAN, R
    HUISMAN, HG
    LENS, P
    JOURNAL OF VIROLOGICAL METHODS, 1993, 43 (02) : 177 - 188
  • [43] Genotypic resistance analyses of plasma HIV-1 RNA in patients failing to the maintenance therapy in Trilege trial
    Descamps, D
    Calvez, V
    Flandre, P
    Pialoux, G
    Raffi, F
    Delaugerre, C
    Collin, G
    Meiffrédy, V
    Peytavin, G
    Aboulker, JP
    Brun-Vézinet, F
    AIDS, 1998, 12 : S11 - S11
  • [44] Cerebrospinal-fluid HIV-1 RNA and drug concentrations after treatment with lamivudine plus zidovudine or stavudine
    Foudraine, NA
    Hoetelmans, RMW
    Lange, JMA
    de Wolf, F
    van Benthem, BHB
    Mass, JJ
    Keet, IPM
    Portegies, P
    LANCET, 1998, 351 (9115): : 1547 - 1551
  • [45] HIV-1 reverse transcriptase codon 215 mutation in plasma RNA: Immunologic and virologic responses to zidovudine
    Rey, D
    Hughes, M
    Pi, JT
    Winters, M
    Merigan, TC
    Katzenstein, DA
    JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES AND HUMAN RETROVIROLOGY, 1998, 17 (03): : 203 - 208
  • [46] HIV-1, THE BRAIN, AND COMBINATION THERAPY
    PORTEGIES, P
    LANCET, 1995, 346 (8985): : 1244 - 1245
  • [47] Emergence of dual resistance to zidovudine and lamivudine in HIV-1-infected patients treated with zidovudine plus lamivudine as initial therapy
    Kuritzkes, DR
    Shugarts, D
    Bakhtiari, M
    Poticha, D
    Johnson, J
    Rubin, M
    Gingeras, TR
    Kennedy, M
    Eron, JJ
    JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 2000, 23 (01) : 26 - 34
  • [48] GENE-THERAPY TO HIV-1 INFECTION - RNA DECOYS AND COMBINATION APPROACHES
    LISZIEWICZ, J
    SUM, D
    SMYTHE, J
    LORI, F
    PENG, B
    TRAPNELL, B
    ROSSI, J
    GALLO, RC
    JOURNAL OF CELLULAR BIOCHEMISTRY, 1994, : 221 - 221
  • [49] Persistence of zidovudine-resistance mutations in HIV-1 isolates from patients removed from zidovudine therapy for at least 3 years and switched to a stavudine-containing regimen
    Pellegrin, I
    Garrigue, I
    Caumont, A
    Pellegrin, JL
    Merel, P
    Schrive, MH
    Bonot, P
    Fleury, H
    AIDS, 2001, 15 (08) : 1071 - 1073
  • [50] Transient detection of plasma HIV-1 RNA during postexposure prophylaxis
    Puro, V
    Calcagno, G
    Anselmo, M
    Benvenuto, G
    Trabattoni, D
    Clerici, M
    Ippolito, G
    INFECTION CONTROL AND HOSPITAL EPIDEMIOLOGY, 2000, 21 (08): : 529 - 531
12345